Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab plus chemotherapy for relapsed/refractory B- or T-cell ALL or lymphoblastic lymphoma in children and young adults
MOH_2018-11-25_004803Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of daratumumab in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL) (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Complete response rate. Started Jun 2018; status: completed.
02
Drugs
daratumumab
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on MOH_2018-11-25_004803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-11-25_004803.